Delcath Systems Inc
DCTH8.640USD
0.000
收盤 11/07, 16:00（美東）報價延遲15分鐘
305.07M總市值
254.65本益比TTM
關於 Delcath Systems Inc 公司
Delcath Systems, Inc. 是一家專注於治療原發性和轉移性肝癌的介入腫瘤學公司。該公司的產品 HEPZATO KIT（注射用 Hepzato（美法侖）/肝臟輸送系統）和 CHEMOSAT 美法侖肝臟輸送系統（CHEMOSAT）經皮肝灌注 (PHP) 旨在向肝臟施用高劑量化療藥物，同時在 PHP 過程中控制全身暴露和相關副作用。HEPZATO KIT 是一種藥物/設備組合產品，旨在將高劑量化療藥物直接輸送到肝臟，同時限制全身暴露和相關副作用。在歐洲，肝臟輸送系統是一種獨立的醫療設備，具有與 HEPZATO KIT 相同的設備組件，但沒有鹽酸美法侖，並以 CHEMOSAT 的商品名獲准銷售。在美國，HEPZATO 受美國食品藥品管理局 (FDA) 的藥品監管。
Delcath Systems Inc簡介
公司代碼DCTH
公司名稱Delcath Systems Inc
上市日期Oct 19, 2000
CEOMr. Gerard J. Michel
員工數量96
證券類型Ordinary Share
年結日Oct 19
公司地址566 Queensbury Avenue
城市QUEENSBURY
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編12804
電話15187438892
網址https://delcath.com/
公司代碼DCTH
上市日期Oct 19, 2000
CEOMr. Gerard J. Michel
Delcath Systems Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Gerard J. Michel
Mr. Gerard J. Michel
Chief Executive Officer, Director
Chief Executive Officer, Director
319.33K
--
Ms. Sandra Pennell
Ms. Sandra Pennell
Chief Financial Officer
Chief Financial Officer
70.30K
+15.15%
Mr. Kevin Muir
Mr. Kevin Muir
General Manager - Interventional Oncology
General Manager - Interventional Oncology
21.61K
+16.30%
Mr. John Richard Sylvester
Mr. John Richard Sylvester
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
10.55K
--
Ms. Martha S. Rook, Ph.D.
Ms. Martha S. Rook, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. David Hoffman
Mr. David Hoffman
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
--
--
Dr. Bridget A. Martell, M.D.
Dr. Bridget A. Martell, M.D.
Independent Director
Independent Director
--
--
Dr. Vojislav Vukovic, M.D., Ph.D.
Dr. Vojislav Vukovic, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Elizabeth Czerepak
Ms. Elizabeth Czerepak
Independent Director
Independent Director
--
--
Mr. Steven A.J. Salamon
Mr. Steven A.J. Salamon
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Gerard J. Michel
Mr. Gerard J. Michel
Chief Executive Officer, Director
Chief Executive Officer, Director
319.33K
--
Ms. Sandra Pennell
Ms. Sandra Pennell
Chief Financial Officer
Chief Financial Officer
70.30K
+15.15%
Mr. Kevin Muir
Mr. Kevin Muir
General Manager - Interventional Oncology
General Manager - Interventional Oncology
21.61K
+16.30%
Mr. John Richard Sylvester
Mr. John Richard Sylvester
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
10.55K
--
Ms. Martha S. Rook, Ph.D.
Ms. Martha S. Rook, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Mr. David Hoffman
Mr. David Hoffman
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
--
--
收入明細
單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
業務USD
名稱
營收
佔比
HEPZATO KIT
22.50M
93.14%
CHEMOSAT
1.66M
6.86%
暫無數據
業務
地區
業務USD
名稱
營收
佔比
HEPZATO KIT
22.50M
93.14%
CHEMOSAT
1.66M
6.86%
股東統計
更新時間: 10月22日 週三
更新時間: 10月22日 週三
持股股東
股東類型
持股股東
持股股東
佔比
Rosalind Advisors, Inc.
9.35%
The Vanguard Group, Inc.
4.69%
BlackRock Institutional Trust Company, N.A.
4.45%
Deerfield Management Company, L.P.
2.32%
Citadel Advisors LLC
2.30%
其他
76.89%
持股股東
持股股東
佔比
Rosalind Advisors, Inc.
9.35%
The Vanguard Group, Inc.
4.69%
BlackRock Institutional Trust Company, N.A.
4.45%
Deerfield Management Company, L.P.
2.32%
Citadel Advisors LLC
2.30%
其他
76.89%
股東類型
持股股東
佔比
Hedge Fund
20.91%
Investment Advisor
17.88%
Investment Advisor/Hedge Fund
7.96%
Research Firm
3.34%
Individual Investor
2.72%
Venture Capital
2.36%
Pension Fund
0.41%
Bank and Trust
0.09%
Insurance Company
0.03%
其他
44.30%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
226
18.53M
52.97%
-953.22K
2025Q2
183
17.20M
49.27%
-551.68K
2025Q1
171
16.12M
46.80%
-1.98M
2024Q4
141
14.61M
45.75%
-298.57K
2024Q3
113
11.18M
39.89%
-3.98M
2024Q2
94
11.26M
40.31%
-2.23M
2024Q1
81
9.17M
35.81%
-967.18K
2023Q4
82
7.09M
31.51%
-2.72M
2023Q3
76
8.38M
57.84%
+174.15K
2023Q2
68
6.41M
45.63%
+3.12M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Rosalind Advisors, Inc.
3.30M
9.43%
-113.08K
-3.31%
Jun 30, 2025
The Vanguard Group, Inc.
1.61M
4.6%
+216.71K
+15.55%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.56M
4.45%
+1.39M
+821.60%
Jun 30, 2025
Deerfield Management Company, L.P.
812.56K
2.32%
-545.00
-0.07%
Jun 30, 2025
Citadel Advisors LLC
803.21K
2.3%
+677.66K
+539.74%
Jun 30, 2025
Geode Capital Management, L.L.C.
703.17K
2.01%
+394.90K
+128.10%
Jun 30, 2025
Vivo Capital, LLC
569.53K
1.63%
-180.67K
-24.08%
Jun 30, 2025
Marshall Wace LLP
483.26K
1.38%
+483.26K
--
Jun 30, 2025
State Street Investment Management (US)
473.89K
1.35%
+360.15K
+316.63%
Jun 30, 2025
Oberweis Asset Management, Inc.
419.40K
1.2%
+57.20K
+15.79%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
Simplify Propel Opportunities ETF
4.24%
Fidelity Digital Health ETF
0.8%
ALPS Medical Breakthroughs ETF
0.22%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.06%
iShares Micro-Cap ETF
0.06%
iShares Russell 2000 Growth ETF
0.02%
Global X Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 ETF
0.01%
查看更多
Simplify Propel Opportunities ETF
佔比4.24%
Fidelity Digital Health ETF
佔比0.8%
ALPS Medical Breakthroughs ETF
佔比0.22%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
佔比0.06%
iShares Micro-Cap ETF
佔比0.06%
iShares Russell 2000 Growth ETF
佔比0.02%
Global X Russell 2000 ETF
佔比0.01%
ProShares UltraPro Russell2000
佔比0.01%
Proshares Ultra Russell 2000
佔比0.01%
iShares Russell 2000 ETF
佔比0.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
